Trastuzumab Emtansine (Solution) provides a HER2-targeting antibody-drug conjugate (ADC) in solution form for breast cancer and oncology research. Also known as T-DM1, it combines trastuzumab with DM1, a potent maytansinoid microtubule inhibitor and specifically supports studies of HER2-directed cytotoxicity, targeted drug delivery, and antibody-mediated cancer cell targeting.
Key Features and Benefits
- HER2-Targeting ADC: Combines the HER2-directed monoclonal antibody trastuzumab with the cytotoxic DM1 payload.
- DM1 Payload: Contains a maytansinoid microtubule inhibitor that specifically supports investigation of ADC-mediated cytotoxicity.
- HER2 Recognition: Supports investigation of HER2 expression, antibody binding, internalization, and tumor-targeting mechanisms.
- Non-Cleavable Linker: Uses a stable thioether linker (SMCC) that specifically connects DM1 to trastuzumab and supports intracellular processing.
- Targeted Payload Delivery: Supports investigation of antibody-mediated DM1 delivery to HER2-expressing cancer cells.
- Microtubule Disruption: DM1 inhibits microtubule dynamics, specifically supporting studies of mitotic arrest and cancer cell death.
- HER2 Signaling Research: The trastuzumab component specifically supports investigation of HER2 receptor signaling and antibody-mediated biological effects.
- Solution Formulation: Provides the ADC in liquid form for research workflows requiring a solution preparation.
Applications
- HER2-Positive Breast Cancer Research: Supports investigation of HER2-targeted ADC mechanisms in HER2-positive breast cancer models.
- HER2-Expressing Cancer Research: Useful for studying ADC targeting and cytotoxicity in cancer models with HER2 expression.
- Gastric Cancer Research: Supports evaluation of HER2-directed ADC strategies in relevant gastric cancer models.
- ADC Research: Useful for investigating antibody binding, cellular uptake, intracellular processing, and payload activity.
- Targeted Cancer Research: Supports investigation of antibody-mediated delivery of DM1 to HER2-expressing cancer cells.
- Cell-Based Cancer Assays: Useful for evaluating HER2-dependent binding, internalization, cytotoxicity, and apoptosis.
- Mechanism-of-Action Studies: Supports investigation of HER2 targeting, DM1-mediated microtubule inhibition, and associated cellular responses.
- Comparative ADC Research: Useful for comparing HER2-targeted ADCs with different linker systems and cytotoxic payloads.
- Drug Resistance Research: Supports investigation of cellular mechanisms associated with reduced sensitivity to HER2-targeted ADCs.
Storage and Handling
- Storage: Store according to the product specification under recommended temperature conditions. Protect the solution from excessive heat and repeated freeze-thaw cycles.
- Handling: Handle using appropriate procedures for antibody-drug conjugates and cytotoxic research materials. Maintain conditions that preserve antibody stability, conjugate integrity, and solution quality.
Trastuzumab Emtansine (Solution) combines HER2-directed antibody targeting with the microtubule-disrupting DM1 payload and specifically supports HER2-positive breast cancer, ADC, targeted drug delivery, and oncology research.
AxisPharm offers 5000+ PEG Linkers with high purity. Different kinds of PEG Reagents may be available by custom synthesis.
